Nitric oxide as a physiopathological factor in neuropsychiatric disorders

In Vivo

Volumn 18, Issue 3, 2004, Pages 377-390

  Akyol, Omer ^a   Zoroglu, Salih ^b   Armutcu, Ferah ^c   Sahin, Semsettin ^d   Gurel, Ahmet ^c  

^a HACETTEPE UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

^d GAZIOSMANPASA UNIVERSITY   (Turkey)

Author keywords

Alzheimer's disease; Autism; Depression; Mood disorder; Nitric oxide; Nitric oxide synthases; Parkinson's disease; Review; Schizophrenia

Indexed keywords

7 NITROINDAZOLE; ALPHA TOCOPHEROL; ARGINASE INHIBITOR; ASCORBIC ACID; BETA CAROTENE; DOPAMINE; ENZYME INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN; OMEGA 3 FATTY ACID; OXYGEN RADICAL; PAROXETINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

AUTISM; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; ENZYME ACTIVITY; LEARNING; MAJOR DEPRESSION; MEMORY; MENTAL DISEASE; MOOD DISORDER; NEUROLOGIC DISEASE; NORADRENALIN RELEASE; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; REVIEW; SCHIZOPHRENIA;

EID: 4043106393     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (138)

1. Black MD, Selk DE, Hitchcock JM, Wettstein JG and Sorensen SM: On the effect of neonatal nitric oxide synthase inhibition rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology 38: 1299-1306, 1999.
2. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA and Jones EG: Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50: 169-177, 1993.
3. Das I, Khan NS, Puri BK, Sooranna SR, de Belleroche J and Hirsch SR: Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212: 375-380, 1995.
4. Deutsch SI, Rosse RB, Schwartz BL, Fay-McCarthy M, Rosenberg PB and Fearing K: Methylene blue adjuvant therapy of schizophrenia. Clin Neuropharmacol 20: 357-363, 1997.
5. Herken H, Uz E, Ozyurt H and Akyol O: Red blood cell nitric oxide levels in patients with schizophrenia. Schizophr Res 52: 289-290; 2001.
6. Herken H, Uz E, Ozyurt H, Sogut S, Virit O and Akyol O: Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6: 66-73, 2001.
7. Savas HA, Herken H, Yurekli M, Uz E, Tutkun H, Zoroglu SS, Ozen ME, Cengiz B and Akyol O: Possible role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 45: 57-61, 2002.
8. Lombard J: Autism: a mitochondrial disorder? Med Hypotheses 50: 497-500, 1998.
9. Johnson S: Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson's disease? Med Hypotheses 56: 641-645, 2001.
10. Fatemi SH, Cuadra AE, El-Fakahany EE, Sidwell RW and Thuras P: Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. Neuroreport 11: 1493-1496, 2000.
11. Koltuksuz U, Irmak MK, Karaman A, Uz E, Var A, Ozyurt H and Akyol O: Testicular nitric oxide levels after unilateral testicular torsion/detorsion in rats pretreated with caffeic acid phenethyl ester. Urol Res 28: 360-363, 2000.
12. Totan Y, Cekic O, Borazan M, Uz E, Sogut S and Akyol O: Plasma malondialdehyde and nitric oxide levels in age related macular degeneration. Br J Ophthalmol 85: 1426-1428, 2001.
13. Fossier P, Blanchard B, Ducrocq C, Leprince C, Tauc L and Baux G: Nitric oxide transforms serotonin into an inactive form and this affects neuromodulation. Neuroscience 93: 597-603, 1999.
14. Brown GC: Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 369: 136-139, 1995.
15. Shen W, Hintze TH and Wolin MS: Nitric oxide. An important signalling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 92: 3505-3512, 1995.
16. Kuo PC and Schroeder RA: The emerging multifaceted roles of nitric oxide. Ann Surg 221: 220-235, 1995.
17. Szabo C, Salzman AL and Ischiropoulos H: Peroxynitrite-mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and haemorrhagic shock and ischemia-reperfusion injury. FEBS Lett 372: 229-232, 1995.
18. Kirkeboen KA and Strand QA: The role of nitric oxide in sepsis-an overview. Acta Anaesthesiol Scand 43: 275-288, 1999.
19. Mayer B and Hemmens B: Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 22: 477-481, 1997.
20. Xie Q-W and Nathan C: The high-output nitric oxide pathway: role and regulation. J Leukocyte Biol 56: 576-582, 1994.
21. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, Malinski T and Luscher TF: Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 101: 1530-1537, 1998.
22. Xia Y and Zweier JL: Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc Natl Acad Sci USA 94: 6954-6958, 1997.
23. Kelm M and Schrader J: Control of coronary vascular tone by nitric oxide. Circ Res 66: 1561-1575, 1990.
24. Lancaster JR: A tutorial on the diffusibility and reactivity of free nitric oxide. Nitric Oxide 1: 18-30, 1997.
25. Lancaster JR: Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 91: 8137-8141, 1994.
26. Kerwin JF, Lancaster JR and Feldman PL: Nitric oxide: a new paradigm for second messengers, J Med Chem 38: 4343-4362, 1995.
27. Bogdan C: Nitric oxide and the regulation of gene expression. Trends Cell Biol 11: 66-75, 2001.
28. Dierks EA and Burstyn JN: Nitric oxide (NO), the only nitrogen monoxide redox form capable of activating soluble-guanylyl cyclase. Biochem Pharmacol 51: 1593-1600, 1996.
29. Hobbs AJ and Ignarro LJ: Nitric oxide-cyclic GMP signal transduction system. Meth Enzymol 269: 134-148, 1996.
30. Blum-Degen D, Heinemann T, Lan J, Pedersen V, Leblhuber F, Paulus W, Riederer P and Gerlach M: Characterization and regional distribution of nitric oxide synthase in the human brain during normal ageing. Brain Res 834: 128-135, 1999.
31. Snyder SH and Bredt DS: Nitric oxide as a neuronal messenger. Trends Pharmacol Sci 12: 125-128, 1991.
32. Kiss JP and Vizi ES: Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 24: 211-215, 2001.
33. Simmons ML and Murphy S: Induction of nitric oxide synthase in glial cells. J Neurochem 59: 897-905, 1992.
34. Garthwaite J and Boulton CL: Nitric oxide signaling in the central nervous system. Annu Rev Physiol 57: 683-706, 1995.
35. Brenman JE and Bredt DS: Synaptic signaling by nitric oxide. Curr Opin Neurobiol 7: 374-378, 1997.
36. Ohkuma S and Katsura M: Nitric oxide and peroxynitrite as factors to stimulate neurotransmitter release in the CNS. Prog Neurobiology 64: 97-108, 2001.
37. Barbour B and Housser M: Intersynaptic diffusion of neurotransmitter. Trends Neurosci 20: 377-384, 1997
38. Garris PA, Ciolkowski EL, Pastore P and Wightman RM: Efflux of dopamine from the synaptic cleft in the nucleus accumbens of the rat brain. J Neurosci 14: 6084-6093, 1994.
39. Gally JA, Montague PR Reeke GN Jr and Edelman GM: The NO hypothesis: Possible effects of a short-lived, rapidly diffusible signal in the development and function of the nervous system. Proc Natl Acad Sci USA 87: 3547-3551, 1990.
40. Vizi ES: Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol Rev 52: 63-90, 2000.
41. Vizi ES and Kiss JP: Neurochemistry and pharmacology of the major hippocampal transmitter systems: Synaptic and nonsynaptic interactions. Hippocampus 8: 566-607, 1998.
42. Kiss JP: Role of nitric oxide in the regulation of monoaminergic neurotransmission. Brain Res Bull 52: 459-466, 2000.
43. Pogun S, Baumann MH and Kuhar MJ: Nitric oxide inhibits [3H]dopamine uptake. Brain Res 641: 83-91, 1994.
44. Lonart G and Johnson KM: Characterization of nitric oxide generator-induced hippocampal [3H]norepinephrine release. II. The role of calcium, reverse norepinephrine transport and cyclic 3',5'-guanosine monophosphate. J Pharmacol ExpTher 275: 14-22, 1995.
45. Mahadic SP and Mukherjee S: Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 19: 1-17, 1996.
46. Mahadic SP and Growda S: Antioxidants in the treatment of schizophrenia. Drugs Today 32: 1-13, 1996.
47. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H and Savas HA: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 26: 995-1005, 2002.
48. Zhang F and Dryhurst G: Effects of 1-cysteine on the oxidative chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37: 1084-1098, 1994.
49. Cadet JL and Kahler LA: Free radical mechanisms in schizophrenia and tardive dyskinesia. Neurosci Biobehav Rev 18: 457-467, 1994.
50. Patel M, Day BJ, Crapo JD, Fridovich I and McNamara JO: Requirement for superoxide in excitotoxic cell death. Neuron 16: 345-355, 1996.
51. Beckman JS, Chen J, Ischiropoulos H and Crow JP: Oxidative chemistry of peroxynitrite. Methods Enzymol 233: 229-240, 1994.
52. Marla SS, Lee J and Groves JT: Peroxynitrite rapidly permeates phospholipid bilayers. Proc Natl Acad Sci USA 94: 14243-14248, 1997.
53. Ioannidis I and de Groot H: Cytotoxicity of nitric oxide in FU5 hepatoma cells: evidence for co-operative action with hydrogen peroxide. Biochem J 296: 341-345, 1993.
54. Fukui T, Ishizaka N, Rajagopalan S, Laursen JB, Capers Q 4th, Taylor WR, Harrison DG, de Leon H, Wilcox JN and Griendling KK: p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 80: 45-51, 1997.
55. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J, Harrison J, Martin JC and Tsai M: Kinetics of superoxide dismutase- and iron-catalysed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 298: 438-445, 1992.
56. Moellering D, McAndrew J, Patel RP, Cornwell T, Lincoln T, Cao X, Messina J, Forman HJ and Darley-Usmar VM: Nitric oxide dependent induction of glutathione synthesis through increased activity of c-glutamylcysteine synthetase. Arch Biochem Biophys 358: 74-82, 1998.
57. Porasuphatana S, Tsai P and Rosen GM: The generation of free radicals by nitric oxide synthase. Comp Biochem Physiol Part C 134: 281-289, 2003.
58. Gattaz WF, Kollish M, Thuren T, Virtanen JA and Kunnunen PKJ: Increased plasma phospholipase-A activity in schizophrenic patients: reduction after neuroleptic treatment. Biol Psychiatry 22: 421-426, 1987.
59. Noponen M, Sanfilipo M, Samanich K, Ryer H, Ko G, Angrist B, Wolkin A, Duncan E and Rotrosen J: Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol Psychiatry 34: 641-649, 1993.
60. Gattaz WF, Schmitt A and Maras A: Increased platelet phospholipase A2 activity in schizophrenia. Schizophr Res 16: 1-6, 1995.
61. Fenton WS, Hibbeln J and Knable M: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry 47: 8-21, 2000.
62. Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, Ellis K and Skinner FS: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res 12: 53-61, 1994.
63. Yao JK, van Kammen DP and Welker JA: Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophr Res 13: 217-226, 1994.
64. Horrobin DF, Manku MS, Hillman H, Iain A and Glen M: Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 30: 795-805, 1991.
65. Yao JK, Leonard S and Reddy RD: Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 42: 7-17, 2000.
66. Mahadik SP, Sitasawas S and Mulchandani M: Membrane peroxidation and the neuropathology of schizophrenia. In: Peet M, Glen I and Horrobin DF (Eds.), Phospholipid Spectrum Disorder in Psychiatry. Marius Press, Lancashire, UK, pp. 99-111, 1999.
67. Taddei S, Virdis A, Ghiadoni L, Magagna A and Salvetti A: Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 29: 274-279, 1997.
68. Kelly FJ and Tetley TD: Nitrogen dioxide depletes uric acid and ascorbic acid but not glutathione from lung lining fuid. J Biochem 325: 95-99, 1997.
69. Patel RP, Diczfalusy U, Dzeletovic S, Wilson MT and Darley-Usmar VM: Formation of oxysterols during oxidation of low density lipoprotein by peroxynitrite, myoglobin, and copper. J Lipid Res 37: 2361-2371, 1996.
70. Lymar SV and Hurst JK: Carbon dioxide: physiological catalysis for peroxynitrite-mediate cellular damage or cellular protectant. Chem Res Toxicol 9: 845-850, 1996.
71. Hoglen NC, Waller SC, Sipes IG and Liebler DC: Reactions of peroxynitrite with gamma-tocopherol. Chem Res Toxicol 10: 401-407, 1997.
72. Akyol O: Increased lipid peroxidation in schizophrenia: a marker of membrane breakdown. Eur Psychiatry (Supplement 1) 17: 75S, 2002.
73. Evans PH: Free radicals in brain metabolism and pathology. Br Med Bull 49: 577-587, 1993.
74. Karcon CN, Griffin WS, Mrak RE, Hussain M, Dawson TM, Snyder SH, Moore NC and Sturner WQ: Nitric oxide synthase (NOS) in schizophrenia: increases in cerebellar vermis. Mol Chem Neuropathol 27: 275-284, 1996.
75. Das I, Khan NS, Puri BK, Sooranna SR, deBelleroche J and Hirsch SR: Elevated platelet calcium mobilization and nitric oxide synthase activity may reflect abnormalities in schizophrenic brain. Biochem Biophys Res Commun 212: 375-380, 1995.
76. Zoroglu SS Herken H, Yurekli M, Uz E, Tutkun H, Savas HA, Bagci C, Ozen ME, Cengiz B, Cakmak EA, Dogru MI and Akyol O: The possible pathophysiological role of plasma nitric oxide and adrenomedullin in schizophrenia. J Psychiatric Res 36: 309-315, 2002.
77. Yanik M, Vural H, Kocyigit A, Tutkun H, Zoroglu SS, Herken H, Savas HA, Koylu A and Akyol O: Is the arginine-nitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology 47: 61-65, 2003.
78. Giovannoni G, Heales SJ, Silver NC, O'Riodan J, Miller RF, Land JM, Clark JB and Thompson EJ: Raised serum nitrate and nitrite levels in patients with multiple sclerosis. J Neurol Sci 145: 77-81, 1997.
79. Richards AM, Nichoils MG, Lewis L and Lainch-Bury JG: Adrenomedullin. Clin Sci 91: 3-16, 1996.
80. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falka P and Bogerts B: Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83: 867-875, 1998.
81. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK and Dikshit M: Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 158: 140-145, 2001.
82. Weinberger DR: Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669, 1987.
83. Bloom FE: Advancing neurodevelopmental origin for schizophrenia. Arch Gen Psychiatry 50: 224-227, 1993.
84. Black MD, Selk DE, Hitchcock JM, Wettstein JG and Sorensen SM: On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology 38: 1299-1306, 1999.
85. Vaid RR, Yee BK, Shalev U, Rawlins JN, Weiner I, Feldon J and Totterdell S: Neonatal nonhandling and in utero prenatal stress reduce the density of NADPH-diaphorase-reactive neurons in the fascia dentata and Ammon's horn of rats. J Neurosci 17: 5599-5609, 1997.
86. Deliconstantinos S and Villiotou V: NO synthase and xanthine oxidase activities of rabbit brain synaptosomes: peroxynitrite formation as a causative factor of neurotoxicity. Neurochem Res 21: 51-56, 1996.
87. Harvey BE: Affective disorders and nitric oxide: a role in pathways to relapse and refractoriness? Hum Psychopharmacol 11: 309-319, 1996.
88. Amsterdam JGC and Opperhuizen A: Nitric oxide and biopterin in depression and stress. Psychiatry Res 85: 33-38, 1999.
89. McDonald EM, Mann AH and Thomas HC: Interferons as mediators of psychiatric morbidity: an investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 2: 1175-1178, 1987.
90. Selley ML: Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression. J Affect Disord 2004 (Article in press).
91. Suzuki E, Yagi G, Nakaki T, Kanba S and Asai M: Elevated plasma nitrate levels in depressive states. J Affect Disord 63: 221-224, 2001.
92. Yildiz F, Erden BF, Ulak G, Utkan T and Gacar N: Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 149: 41-44, 2000.
93. Elgun S and Kumbasar H: Increased serum arginase activity in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 24: 227-232, 2000.
94. Sogut S, Zoroglu SS, Ozyurt H, Yilmaz HR, Ozugurlu F, Sivasli E, Yetkin O, Yanik M, Tutkun H, Savas HA, Tarakcioglu M and Akyol O: The changes in nitric oxide levels and antioxidant enzyme activities may have a role in the pathophysiological mechanisms involved in autism. Clin Chim Acta 331: 111-117, 2003.
95. Zoroglu SS, Yurekli M, Meram I, Sogut S, Tutkun H, Yetkin O, Sivasli E, Savas HA, Yanik M, Herken H and Akyol O: Pathophysiological role of nitric oxide and adrenomedullin in autism. Cell Biochem Funct 21: 55-60, 2003.
96. Vancassel S, Durand G, Barthelemy C, Lejeune B, Martineau J, Guilloteau D, Andres C and Chalon S: Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 65: 1-17, 2001.
97. Bell JG, Sargent JR, Tocher DR and Dick JR: Red blood cell fatty acid compositions in a patient with autistic spectrum disorder: a characteristic abnormality in neurodevelopmental disorders? Prostaglandins Leukot Essent Fatty Acids 63: 21-25, 2000.
98. Kane PC and Schauss MA: Peroxisomal disturbances in children with epilepsy, hypoxia, and autism. Prostaglandins Leukot Essent Fatty Acids 57: 265, 1997.
99. Olanow CW and Tatton WG: Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123-144, 1999.
100. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P and Marsden CD: Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389, 1989.
101. Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D and Beal MF: Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport 11: 1265-1268, 2000.
102. Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM and Przedborski S: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Nat Med 5: 1403-1409, 1999.
103. Hantraye P, Brouillet E, Ferrante R, Palfi S, Dolan R, Matthews RT and Beal MF: Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med 2: 1017-1021, 1996.
104. Choi J-Y, ParkC-S, Kim D-J, Cho M-H, Jin BK, Pie J-E and Chung W-G: Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. NeuroToxicology 23: 367-374, 2002.
105. Eve DJ, Nisbet AP, Kingsbury AE, Hewson EL, Daniel SE, Lees AJ, Marsden CD and Foster OJF: Basal ganglia neuronal nitric oxide synthase mRNA expression in Parkinson's disease. Mol Brain Res 63: 62-71, 1998.
106. Smythies J and Galzigna L: The oxidative metabolism of catecholamines in the brain: a review. Biochim Biophys Acta 1380: 159-162, 1998.
107. Good P, Hsu A, Werner P, Perl D and Olanow C: Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57: 338-342, 1998.
108. Rettori D, Tang Y, Dias LC Jr and Cadenas E: Pathways of dopamine oxidation mediated by nitric oxide. Free Radic Biol Med 33: 685-690, 2002.
109. Riobo NA, Schopfer FJ, Boveris AD, Cadenas E and Poderoso JJ: The reaction of nitric oxide with 6-hydroxydopamine: implications for Parkinson's disease. Free Radic Biol Med 32: 115-121, 2002.
110. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P and Halliwell B: Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203, 1997.
111. Lo H-S, Hogan EL and Soong B-W: 5'-Flanking region polymorphism of the neuronal nitric oxide synthase gene with Parkinson's disease in Taiwan. J Neurol Sci 194: 11-13, 2002.
112. Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML and Poderoso JJ: Overexpression of neutrophils neuronal nitric oxide synthase in Parkinson's disease. Nitric oxide. Biol Chem 4: 534-539, 2000.
113. Barthwal MK, Srivastave N, Shokla R, Nag D, Seth PK, Srimal RC and Dikshit M: Polymorphonuclear leukocytes nitrite content and antioxidant enzymes in Parkinson's disease patients. Acta Neurol Scand 100: 300-304, 1999.
114. Markesbery WR and Lovell MA: Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36, 1998.
115. Law A, Gauthier S and Quirion R: Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of Alzheimer's type. Brain Res Rev 35: 73-96, 2001.
116. Varadarajan S, Yatin S, Aksenova M and Butterfield DA: Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol 130: 184-208, 2000.
117. Yang SN, Hsieh WY, Liu DD, Tsai LM, Tung CS and Wu JN: The involvement of nitric oxide in synergistic neuronal damage induced by beta-amyloid peptide and glutamate in primary rat cortical neurons. Chin J Physiol 41: 175-179, 1998.
118. Mattson MP, Rychlik B, Chu C and Christakos S: Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron 6: 41-51, 1991.
119. Munch G, Gasic-Milenkovic J, Dukic-Stefanovic S, Kuhla B, Heinrich K, Riederer P, Huttunen HJ, Founds H and Sajithlal G: Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Exp Brain Res 150: 1-8, 2003.
120. Wong A, Luth HJ, Deuther-Conrad W, Dukic-Stefanovic S, Gasic-Milenkovic J, Arendt T and Munch G: Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res 920: 32-40, 2001.
121. Mahadic SP and Scheffer RE: Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins Leukot Essent Fatty Acids 55: 45-54, 1996.
122. Beauclair L, Vinogradov S, Riney SJ, Csernansky JG and Hollister LE: An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 7: 282-283, 1987.
123. Kanofsky JD and Sandyk R: Antioxidants in the treatment of schizophrenia. Int J Neurosci 62: 97-100, 1992.
124. Tatton WG and Greenwood CE: Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30: 666-672, 1991.
125. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS and Thal LJ: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 336: 1216-1222, 1997.
126. Mattson MP: Existing data suggest that Alzheimer's disease is preventable. Ann NY Acad Sci 924: 153-159, 2000.
127. Sarsilmaz M, Songur A, Ozyurt H, Kus I, Ozen OA, Ozyurt B, Sogut S and Akyol O: Potential role of dietary ω-3 essential fatty acids on some oxidant/antioxidant parameters in rats' corpus striatum: a preliminary animal study on alternative therapeutic approach to schizophrenia. Prostaglandins Leukot Essent Fatty Acids 69: 253-259, 2003.
128. Duncan GE, Sheitman BB and Lieberman JA: An integrated view of pathophysiological models of schizophrenia. Brain Res Rev 29: 250-264, 1999.
129. Deutsch SI, Rosse RB, Billingslea EN, Bellack AS and Mastropaolo J: Modulation of MK-801-elicited mouse popping behavior by galantamine is complex and dose-dependent. Life Sci 73: 2355-2361, 2003.
130. Wiley JL: Nitric oxide synthase inhibitors attenuate phencyclidine-induced disruption of prepulse inhibition. Neuropsychopharmacology 19: 86-94, 1998.
131. Trullas R: Functional NMDA antagonists: a new class of antidepressant agents. In: Skolnick P, Ed. Antidepressants: New Pharmacological Strategies. Humana Press, Totowa, NJ, USA. pp. 103-124, 1997.
132. Harkin AJ, Bruce KH, Craft B and Paul IA: Nitric oxide synthase inhibitors have antidepressant-like properties in mice 1. Acute treatments are active in the forced swim test. Eur J Pharmacol 372: 207-213, 1999.
133. Finkel MS, Lahgrissi-Thode F, Pollock BG and Rong J: Paroxetine is a novel nitric oxide synthasae inhibitor. Psychopharmacol Bull 32: 653-658, 1996.
134. Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL and Dawson TM: Role of neuronal nitric oxide in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)- induced dopaminergic neurotoxicity. Proc Natl Acad Sci USA 93: 4565-4571, 1996.
135. Luth HJ, Munch G and Arendt T: Aberrant expression of NOS isoforms in Alzheimer's disease is structurally related to nitrotyrosine formation. Brain Res 953: 135-143, 2002.
136. Zhu XZ and Luo LG: Effect of nitroprusside (nitric oxide) on endogenous dopamine release from rat striatal slices. J Neurochem 59: 932-935, 1992.
137. Lin AM, Kao LS and Chai CY: Involvement of nitric oxide in dopaminergic transmission in rat striatum: an in vivo electrochemical study. J Neurochem 65: 2043-2049, 1995.
138. Filip M and Przegalinski E: The role of the nitric oxide (NO) pathway in the discriminative stimuli of amphetamine and cocaine. Pharmacol Biochem Behav 59: 703-708, 1998.